Response to inhibition of angiotensin-converting enzyme in human immunodeficiency virus-associated nephropathy: a case report.
The most common chronic nephropathy seen with human immunodeficiency virus (HIV) infection is characterized by heavy proteinuria and rapid deterioration of renal function. We here report the findings in an HIV-seropositive patient with nephrotic-range proteinuria and biopsy-proven HIV-associated nephropathy treated with the angiotensin-converting enzyme (ACE) inhibitor, fosinopril. During treatment periods, the patient demonstrated a significant decrement in 24-hour urinary protein excretion without change in renal function. The patient acted as her own control. After discontinuation of the drug, the 24-hour protein excretion deteriorated to pretreatment levels. ACE inhibition has been reported to decrease proteinuria and to have a beneficial influence on the progression of renal failure in diabetic and nondiabetic renal disease. To date, there is no known therapy for HIV-associated nephropathy. Our preliminary results in this patient suggest the need for long-term studies to assess whether this form of therapy can improve proteinuria over longer periods and, at the same time, ameliorate the progressive form of nephropathy seen in selected HIV-seropositive patients.
Burns
G C
GC
Department of Medicine, St Vincent's Hospital and Medical Center of New York, NY.
Matute
R
R
Onyema
D
D
Davis
I
I
Toth
I
I
D016263:AIDS-Associated Nephropathy / Q000188:drug therapy*; D000328:Adult; D005260:Female; D017328:Fosinopril / Q000627:therapeutic use*; D006801:Humans; D011507:Proteinuria / Q000188:drug therapy
D017328:Fosinopril